Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...7677787980818283848586...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa. (Pubmed Central) -  Jul 29, 2020   
    For patients with locally advanced or metastasized SCCs treatment with cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), has been proposed and so far, treatment of five DEB patients with cetuximab has been published...We also show that EGFR is frequently expressed in DEB-associated SCCs, although there were noticeable differences in the level of expression, which may influence responsiveness to EGFR-targeting therapies. Although only limited experiences with targeted cancer treatments in EB exist, such reports highlight the treatments' effects in this specific cohort and assist our therapeutic decisions.
  • ||||||||||  fluorouracil / Generic mfg., Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  Perioperative Chemotherapies for Patients with Colorectal Liver Metastasis (Pubmed Central) -  Jul 29, 2020   
    In patients with a resectable CRLM, the adjuvant chemotherapy with 5-FU/LV effectively prolongs DFS or RFS. In patients with unresectable CRLM, a neoadjuvant chemotherapy with high response rate and high liver resection rate, such as FOLFOX(or CAPOX, SOX)plus bevacizumab, FOLFOX/FOLFIRI plus cetuximab, or FOLFOXIRI plus bevacizumab, could be an optimal regimen for the conversion therapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Retrospective data, Review, Journal:  Reliability of digital PCR in detecting KRAS mutation in colorectal cancer using plasma sample: A systematic review and meta-analysis. (Pubmed Central) -  Jul 29, 2020   
    In patients with unresectable CRLM, a neoadjuvant chemotherapy with high response rate and high liver resection rate, such as FOLFOX(or CAPOX, SOX)plus bevacizumab, FOLFOX/FOLFIRI plus cetuximab, or FOLFOXIRI plus bevacizumab, could be an optimal regimen for the conversion therapy. Although no significant bias was identified, number of included studies was still quite small, especially in subgroup analysis.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, irinotecan / Generic mfg., Zelboraf (vemurafenib) / Roche
    cetuximab irinotecan vemurafenib (Twitter) -  Jul 28, 2020   
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
    encorafenib, cetuximab, and binimetinib (Twitter) -  Jul 28, 2020   
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Clinical, Journal:  Interobserver reproducibility of tumor uptake quantification with Zr-immuno-PET: a multicenter analysis. (Pubmed Central) -  Jul 25, 2020   
    This study shows that interobserver reproducibility of tumor uptake quantification on Zr-immuno-PET was excellent for SUV and SUV using a standardized manual procedure for tumor segmentation. Semi-automatic delineation was not robust due to limited tumor contrast.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Low UBE4B expression increases sensitivity of chemoresistant neuroblastoma cells to EGFR and STAT5 inhibition. (Pubmed Central) -  Jul 25, 2020   
    In chemoresistant neuroblastoma cells, depletion of UBE4B yielded significantly reduced cell proliferation and migration, and enhanced apoptosis in response to EGFR inhibitor, Cetuximab...Thus, neuroblastoma cells with low UBE4B levels were significantly more sensitive to combined EGFR and STAT5 inhibition than parental cells. These findings may have potential therapeutic implications for patients with 1p36 chromosome LOH and low tumor UBE4B expression.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, everolimus / Generic mfg.
    Journal, PD(L)-1 Biomarker:  Applied precision medicine in metastatic pancreatic ductal adenocarcinoma. (Pubmed Central) -  Jul 24, 2020   
    One patient was treated with nintedanib and achieved stable disease for 6 months. Based on our observations, precision medicine approaches are feasible and implementable in clinical routine and may provide molecular-based therapy recommendations for mPDAC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, paclitaxel / Generic mfg.
    [VIRTUAL] Launching local treatment guidelines for stage IV cancer during COVID-19 pandemic using ESMO MCBS (On-Demand) -  Jul 24, 2020 - Abstract #ESMO2020ESMO_2525;    
    HER2+3 Addition of carboplatin to combination of trastuzumab and paclitaxel every three weeks was confirmed to increase treatment benefit, PFS of 13.8 v 7.6 months (P=.005) (HR, 0.55; 95% CI, 0.46 to 0.64), RR (42% v 29%) MCBS for carboplatin=3, which is the COT (JCO 2006, 24:2786)...mCRC all RAS wild type No change for the use of FOLFRI + cetuximab: MCBS=4 using an infusion pump for 5FU with certain precautions...Pemetrexed with cisplatin is the recommended option for a patient with PS ≥1 and PDL1<50 with MCBS=4...Legal entity responsible for the study: The authors. Funding: Has not received any funding.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer (clinicaltrials.gov) -  Jul 24, 2020   
    P=N/A,  N=8, Active, not recruiting, 
    N=1400 --> 609 Recruiting --> Active, not recruiting | N=27 --> 8 | Trial completion date: Jun 2020 --> Jun 2022 | Trial primary completion date: Jun 2020 --> Jun 2022
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Surgery, Metastases:  Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) -  Jul 23, 2020   
    P1/2,  N=44, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=27 --> 8 | Trial completion date: Jun 2020 --> Jun 2022 | Trial primary completion date: Jun 2020 --> Jun 2022 Trial completion date: Jan 2021 --> Oct 2022 | Trial primary completion date: Jun 2020 --> Oct 2021
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, merestinib (LY2801653) / Eli Lilly
    Clinical, P1 data, Journal:  First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. (Pubmed Central) -  Jul 22, 2020   
    P1
    Trial completion date: Jan 2021 --> Oct 2022 | Trial primary completion date: Jun 2020 --> Oct 2021 Merestinib treatment in patients with advanced cancer demonstrated an acceptable safety profile and potential antitumor activity, supporting its future development in specific disease populations as a monotherapy and/or in combination with other therapies.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma. (Pubmed Central) -  Jul 22, 2020   
    The development of targeted therapies for brain tumors has been concurrent with the development of microcatheter technology, which has made superselective distal intracranial arterial access feasible and safe. In summary, ASCT2-dependent glutamine uptake and subsequent glutamine metabolism are essential for HNSCC tumorigenesis, and the combination of glutamine uptake inhibitors and cetuximab presents a promising strategy for improving the outcomes of HNSCC patients.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, paclitaxel / Generic mfg.
    Clinical, Journal:  Renal Metastases from a Nasal Cavity Mixed Squamous Cell and Adenoid Cystic Carcinoma: A Case Report. (Pubmed Central) -  Jul 22, 2020   
    CONCLUSIONS The particularity of this case relies on the rarity of renal metastasis from ACC, its difficult diagnosis, and the complexity of its management, as no standard chemotherapy has been validated for metastatic ACC, yet. In our case, a weekly carboplatin/paclitaxel/cetuximab regimen was administered leading to a durable tumor stabilization with an excellent patient's quality of life.
  • ||||||||||  CIML NK - Dana / Farber Cancer Institute
    Enrollment open, Combination therapy, Metastases, Immune cell:  CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov) -  Jul 21, 2020   
    P1,  N=12, Recruiting, 
    In our case, a weekly carboplatin/paclitaxel/cetuximab regimen was administered leading to a durable tumor stabilization with an excellent patient's quality of life. Not yet recruiting --> Recruiting
  • ||||||||||  NT219 / Purple Biotech
    Enrollment open, Combination therapy, Metastases:  A Study to Evaluate NT219 Alone and in Combination With ERBITUX (clinicaltrials.gov) -  Jul 21, 2020   
    P1/2,  N=83, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, everolimus / Generic mfg.
    Review, Journal, PD(L)-1 Biomarker, IO Biomarker:  PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. (Pubmed Central) -  Jul 21, 2020   
    A study investigating everolimus (Rad001) with cisplatin and radiotherapy has reported promising 2-year progression free survival and overall survival rates of 85% and 92%. Further clinical trials should follow.